Skip to main content
. 2024 Jan 11;80:101880. doi: 10.1016/j.molmet.2024.101880

Figure 2.

Figure 2

ActRII inhibition plus GLP-1 receptor agonism further decreases adipose tissue mass during weight loss.

A) Weights (g) of iWAT, eWAT, rpWAT, and BAT depots isolated from HFD-fed mice treated for 14 days.

B) Percent difference in fat depot weights compared to control group.

C) Representative iWAT and eWAT sections stained with H&E (10x magnification, scale bar = 100 um).

D) Quantification of average adipocyte size in iWAT and eWAT sections (n = 8: 2 images analyzed per animal, 4 animals per group).

n = 8 mice for control and semaglutide + bimagrumab groups, n = 9 mice for semaglutide and bimagrumab groups unless otherwise indicated.∗p < 0.05, ∗∗p < 0.001, ∗∗∗p < 0.0005, ∗∗∗∗p < 0.0001 for control vs. bimagrumab, semaglutide, and semaglutide + bimagrumab; #p < 0.05, ##p < 0.001, ###p < 0.0005, ####p < 0.0001 for bimagrumab vs. semaglutide and semaglutide + bimagrumab; & p < 0.05, && p < 0.001 for semaglutide vs. semaglutide + bimagrumab.